Ashion Analytics to Present Data on the Value of Comprehensive Genomic Profiling of Gastrointestinal Cancers by Utilizing the GEM ExTra® Test
News provided by
Share this article
Share this article
PHOENIX, Jan. 15, 2021 /PRNewswire/ Ashion Analytics LLC, a CLIA-certified and CAP-accredited clinical laboratory announced today that they will present data at the 2021 American Society for Clinical Oncology Gastrointestinal (ASCO GI) virtual meeting.
Abstract #109
Title:
Genomic profiling of gastrointestinal cancers by comprehensive tumor-normal sequencing
Authors: Fadel S. Alyaqoub, Pawan Noel, Szabolcs Szelinger, Thanemozhi G. Natarajan, Susan M. Dombrowski, Audrey A. Ozols, Laurie J. Goodman, Janine LoBello, Thomas Royce, Gargi D. Basu
Share this article
Share this article
ResearchAndMarkets.com s offering.
The fluoroscopy equipment market is projected to reach USD 7.5 billion by 2025 from USD 5.9 billion in 2020, at a CAGR of 4.8%
Growth in the fluoroscopy equipment market can be attributed to the rising geriatric population, growing prevalence of chronic diseases, advantages of FPDs over image intensifiers, the use of fluoroscopy in pain management, reimbursement cuts for analog radiography systems, and awareness programs, conferences, and funding activities. However, the risk of radiation exposure is expected to limit market growth to a certain extent during the forecast period.
The fixed C-arms segment accounted for the largest market share in 2019.
Global $938 Million Glycobiology Market to 2025
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Glycobiology Market was valued at USD 938.76 Million and is expected to grow at a doubled digit CAGR of 13.83% during the forecast period.
The Global Glycobiology Market is driven by the growing prevalence of chronic diseases such as cancer, diabetics, renal diseases, among others, which has increased the demand for personalized medicines. This in turn has increased the drug discovery process around the globe, which is anticipated to positively impact growth of the market during the forecast period.
Also, increasing grants by different governments especially in the developing nations for R&D activities is further expected to bolster the growth of the market over the next few years. Furthermore, increasing research activities in glycomics, technological advancements and rising government initiatives is also among the major driver
Share this article
NAPLES, Fla., Jan. 15, 2021 /PRNewswire/
HealthLynked Corp. (OTCQB: HLYK), a global healthcare network focused on care management of its members and a provider of healthcare technologies that connects doctors, patients and medical data, announced today that it has converted $1.3 million of its debt to equity, eliminated the security interest on its assets. This will allow the company to obtain a bank line of credit at current low interest rates.
Iconic Holdings, LLC, an early investor in HealthLynked, agreed to convert all of its convertible debt totaling $1.3 million, including principal and accrued interest, into 13.5 million HealthLynked common shares and 13.5 million five-year warrants with an exercise price of $0.30 per share in exchange for a 180 day leak out provision, 5% of daily volume for the first 90 days and 10% of daily volume for the next 90 days.